Doxorubicin (Adriamycin) --a new anticancer drug
Medical Letter on Drugs and Therapeutics 17(10): 42-43
1975
ISSN/ISBN: 0025-732X PMID: 1055286 Document Number: 84077
Document emailed within 1 workday
Related Documents
Marutaka, M.; Iwagaki, H.; Suguri, T.; Tanaka, N.; Orita, K. 1994: Alterations of membrane fluidity in K562 cells exposed to the anticancer drug adriamycin Research Communications in Molecular Pathology and Pharmacology 85(2): 163-170Hoshino, M.; Koyama, Y.; Sugano, K.; Kanno, M.; Satou, N.; Abe, R. 1989: Enhanced effect of hepatic arterial infused anticancer drugs on rabbit VX-2 carcinoma by means of combination with Lipiodol. Adriamycin versus Lipiodol adriamycin sandwich method and adriamycin suspended in a Lipiodol Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(8 Part 2): 2810-2813
Weisburst, M.R.; Pearlman, E.S.; Capone, R.J. 1980: Doxorubicin (Adriamycin) cardiotoxicity Connecticut Medicine 44(3): 133-136
Weisburst, M.R.; Pearlman, E.S.; Capone, R.J. 1980: Doxorubicin (Adriamycin) cardiotoxicity Connecticut Medicine 44(3): 133-136
Zhang, Q.; Xiang, G.-y.; Long, N.; Lin, J.-l.; Zeng, F.-b. 2005: Anticancer activity of N-(phenylacetyl) doxorubicin combined with folate-targeted PGA Yao Xue Xue Bao 40(11): 1046-1050
Goldenberg, G.J.; Wang, H.; Blair, G.W. 1986: Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia Cancer Research 46(6): 2978-2983
Deffie, A.M.; Alam, T.; Seneviratne, C.; Beenken, S.W.; Batra, J.K.; Shea, T.C.; Henner, W.D.; Goldenberg, G.J. 1988: Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia Cancer Research 48(13): 3595-3602
Hagiwara, A.; Takahashi, T. 1987: A new drug-delivery-system of anticancer agents: activated carbon particles adsorbing anticancer agents In Vivo 1(4): 241-252
Sparano, B.M.; Gordon, G.; Hall, C.; Iatropoulos, M.J.; Noble, J.F. 1982: Safety assessment of new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology Cancer Treatment Reports 66(5): 1145-1158
Van Vleet, J.F.; Ferrans, V.J.; Badylak, S.F. 1982: Effect of thyroid hormone supplementation on chronic doxorubicin (adriamycin)-induced cardiotoxicity and serum concentrations of T3 and T4 in dogs American Journal of Veterinary Research 43(12): 2173-2182
de la Torre, M.; Hao, X.Y.; Larsson, R.; Nygren, P.; Tsuruo, T.; Mannervik, B.; Bergh, J. 1993: Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases Anticancer Research 13(5a): 1425-1430
Jekunen, A.; Lehtovirta, P.; Pyrhönen, S. 1994: Paclitaxel, a new anticancer drug Duodecim; Laaketieteellinen Aikakauskirja 110(13): 1235-1240
Saito, T. 1988: An anticancer drug--carboquone Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(3): 549-554
Johnstone, S.A.; Gelmon, K.; Mayer, L.D.; Hancock, R.E.; Bally, M.B. 2000: In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines Anti-Cancer Drug Design 15(2): 151-160
Akazawa, S.; Yamashina, T.; Konuma, Y.; Takahashi, M.; Ueno, A. 2001: Management of anticancer drug adverse reactions Nihon Rinsho. Japanese Journal of Clinical Medicine 59(Suppl 4): 409-414
Li Dapeng 2005: The anticancer drug Kang-Lai-Te emulsion for infusion Vestnik Rossiiskoi Akademii Meditsinskikh Nauk 2005(9): 32-37
Yamada, T.; Tanaka, N.; Yokoi, K.; Ishikawa, N.; Seya, T.; Horiba, K.; Kanazawa, Y.; Shirakawa, T.; Ohkawa, K.; Kudoh, H.; Koizumi, M.; Yoshioka, M.; Tajiri, T. 2007: Substance P and anticancer drug-induced emesis Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(6): 903-906
Workman, P. 1997: Towards intelligent anticancer drug screening in the post-genome era? Anti-Cancer Drug Design 12(7): 525-531
Capel, I.D.; Leach, D.; Dorrell, H.M. 1983: Vitamin e retards the lipoperoxidation resulting from anticancer drug administration Anticancer Research 3(1): 59-62
Hsiang, Y.H.; Liu, L.F. 1988: Identification of mammalian DNA topoisomerase i as an intracellular target of the anticancer drug camptothecin Cancer Research 48(7): 1722-1726